These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35205815)

  • 1. Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth.
    Chilamakuri R; Agarwal S
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
    Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
    Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Potential of CUDC-907 (Fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening.
    Liao W; Yang W; Xu J; Yan Z; Pan M; Xu X; Zhou S; Zhu Y; Lan J; Zeng M; Han X; Li S; Li Y; Liang K; Gao Y; Peng Q
    Front Pharmacol; 2021; 12():658197. PubMed ID: 34776939
    [No Abstract]   [Full Text] [Related]  

  • 6. CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms.
    Wang Y; Wen J; Sun X; Sun Y; Liu Y; Cheng X; Wu W; Liu Q; Ren F
    Cancer Chemother Pharmacol; 2024 Apr; 93(4):295-306. PubMed ID: 37938423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.
    Kotian S; Zhang L; Boufraqech M; Gaskins K; Gara SK; Quezado M; Nilubol N; Kebebew E
    Clin Cancer Res; 2017 Sep; 23(17):5044-5054. PubMed ID: 28600475
    [No Abstract]   [Full Text] [Related]  

  • 8. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
    Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
    J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy.
    Chilamakuri R; Rouse DC; Yu Y; Kabir AS; Muth A; Yang J; Lipton JM; Agarwal S
    Transl Oncol; 2022 Jan; 15(1):101272. PubMed ID: 34823094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth.
    Chilamakuri R; Rouse DC; Agarwal S
    Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
    Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
    Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
    Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastoma.
    Li M; Hu Y; Wang J; Xu Y; Hong Y; Zhang L; Luo Q; Zhen Z; Lu S; Huang J; Zhu J; Zhang Y; Que Y; Sun F
    Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38063204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFβ1 induced lung and tumor fibrosis.
    Zhang W; Zhang Y; Tu T; Schmull S; Han Y; Wang W; Li H
    Cell Death Dis; 2020 Sep; 11(9):765. PubMed ID: 32943605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer.
    Jian Z; Han Y; Zhang W; Li C; Guo W; Feng X; Li B; Li H
    Cell Biosci; 2022 Aug; 12(1):135. PubMed ID: 35989326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest.
    Cao W; Yao S; Li A; Chen H; Zhang E; Cao L; Zhang J; Hou Y; Dai Z; Chen J; Huang X; Yang L; Cai Z
    J Zhejiang Univ Sci B; 2023 May; 24(5):442-454. PubMed ID: 37190893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
    Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
    Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth.
    Chilamakuri R; Agarwal S
    Curr Oncol; 2022 Sep; 29(9):6508-6522. PubMed ID: 36135081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
    Guo H; Zeng D; Zhang H; Bell T; Yao J; Liu Y; Huang S; Li CJ; Lorence E; Zhou S; Gong T; Jiang C; Ahmed M; Yao Y; Nomie KJ; Zhang L; Wang M
    Oncogene; 2019 Mar; 38(11):1802-1814. PubMed ID: 30361685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer.
    Ji M; Li Z; Lin Z; Chen L
    Am J Cancer Res; 2018; 8(12):2402-2418. PubMed ID: 30662800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.